Digital Precision Hypertension: AI-Driven Monitoring, Personalized Treatment and Real-World Implementation

Hypertension leftovers a leading global health challenge, causal to increased cardiovascular morbidity and mortality despite advances in pharmacotherapy and lifestyle interventions. Traditional hypertension management often follows a one-size-fits-all approach, failing to account for the heterogeneity of patient physiology, genetics, and environmental factors. The emergence of digital precision medicine, empowered by artificial intelligence [AI], is transforming this paradigm by enabling data-driven, patient-specific hypertension care. AI-integrated wearable sensors, mobile health applications, and remote monitoring platforms now facilitate continuous, real-time blood pressure tracking and behavioural analysis. These technologies generate large-scale datasets that can identify hidden patterns, predict risk trajectories, and personalise therapeutic interventions. Machine learning algorithms, when combined with clinical, genomic, and lifestyle data, enhance diagnostic accuracy and treatment optimisation—supporting decisions on drug selection, dosage titration, and lifestyle modification strategies tailored to individual needs. Furthermore, the integration of digital twins and cloud-based analytics provides a comprehensive representation of cardiovascular dynamics, fostering proactive and preventive care models. However, real-world implementation faces challenges including data privacy, interoperability, algorithmic bias, and regulatory compliance. Bridging these gaps requires collaboration among clinicians, data scientists, policymakers, and technology developers to ensure equity and clinical validity. This review explores the intersection of AI, digital monitoring, and precision therapeutics in hypertension management, critically evaluating current advancements, translational hurdles, and emerging opportunities. By merging precision medicine principles with intelligent digital systems, the future of hypertension care is envisioned as predictive, preventive, personalised, and participatory (P4 medicine)—enhancing both clinical outcomes and patient empowerment.

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-11-20
DOI
https://doi.org/10.5281/zenodo.17660165
Primary Topic
Blood Pressure and Hypertension Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Digital Precision Hypertension: AI-Driven Monitoring, Personalized Treatment and Real-World Implementation

Zenodo (CERN European Organization for Nuclear Research)
Blood Pressure and Hypertension Studies
article

Digital Precision Hypertension: AI-Driven Monitoring, Personalized Treatment and Real-World Implementation

article en

Abstract

Hypertension leftovers a leading global health challenge, causal to increased cardiovascular morbidity and mortality despite advances in pharmacotherapy and lifestyle interventions. Traditional hypertension management often follows a one-size-fits-all approach, failing to account for the heterogeneity of patient physiology, genetics, and environmental factors. The emergence of digital precision medicine, empowered by artificial intelligence [AI], is transforming this paradigm by enabling data-driven, patient-specific hypertension care. AI-integrated wearable sensors, mobile health applications, and remote monitoring platforms now facilitate continuous, real-time blood pressure tracking and behavioural analysis. These technologies generate large-scale datasets that can identify hidden patterns, predict risk trajectories, and personalise therapeutic interventions. Machine learning algorithms, when combined with clinical, genomic, and lifestyle data, enhance diagnostic accuracy and treatment optimisation—supporting decisions on drug selection, dosage titration, and lifestyle modification strategies tailored to individual needs. Furthermore, the integration of digital twins and cloud-based analytics provides a comprehensive representation of cardiovascular dynamics, fostering proactive and preventive care models. However, real-world implementation faces challenges including data privacy, interoperability, algorithmic bias, and regulatory compliance. Bridging these gaps requires collaboration among clinicians, data scientists, policymakers, and technology developers to ensure equity and clinical validity. This review explores the intersection of AI, digital monitoring, and precision therapeutics in hypertension management, critically evaluating current advancements, translational hurdles, and emerging opportunities. By merging precision medicine principles with intelligent digital systems, the future of hypertension care is envisioned as predictive, preventive, personalised, and participatory (P4 medicine)—enhancing both clinical outcomes and patient empowerment.

Zenodo (CERN European Organization for Nuclear Research)
Openalex Percentile: Top 35%
Blood Pressure and Hypertension Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Digital Precision Hypertension: AI-Driven Monitoring, Personalized Treatment and Real-World Implementation · Zenodo (CERN European Organization for Nuclear Research) (2025) | TGRS Research Map | TGRS